CCO Treatment Updates

6th International Symposium on Translational Research in Oncology

The annual International Symposium on Translational Research in Oncology has a firmly established reputation as a premier meeting at which the world’s leading researchers gather to present and discuss new directions in oncology research. The focus of the program, now in its sixth year, is on translating the most recent laboratory developments into improved clinical outcomes for cancer patients. CCO is pleased to present this series of CME-certified slidesets summarizing proceedings of the 6th annual meeting—now available for download. CCO encourages its members to download and review these slides, share them with colleagues, and use them in their own presentations. When finished reviewing, be sure to take the test to earn CME credit.

Slideset Modules

Session I: Growth Factors and Growth Factor Receptors

Program Directors:

Dennis J. Slamon, MD, PhD headshotJohn Crown, MD, MPH headshot
  • Dennis J. Slamon, MD, PhD
  • John Crown, MD, MPH

Faculty:

Dennis J. Slamon, MD, PhD headshot
  • Dennis J. Slamon, MD, PhD

CME CREDIT INFORMATION

Release Date: 01/07/08

Expiration Date: 01/06/09


Physicians: maximum of 1.0 AMA PRA Category 1 Credit(s)™

Status: Please log in to view status


Highlights from the Dublin 2007 Translational Research Meeting

Learning Objectives

Upon completion of this activity, participants should be able to:

  • Describe the use of the insulin-like growth factor receptor as a therapeutic target in preclinical models
  • Cite therapeutic agents used to target growth factor receptors on malignant cells
  • Summarize in vitro data regarding the use of growth factor receptors as therapeutic targets

Session I: Growth Factors and Growth Factor Receptors


Highlights from the Dublin 2007 Translational Research Meeting


Format: Microsoft PowerPoint (.ppt) | File size: 2,711 KB

Session II: Steroid Hormonal Receptors and Their Manipulation

Program Directors:

Dennis J. Slamon, MD, PhD headshotJohn Crown, MD, MPH headshot
  • Dennis J. Slamon, MD, PhD
  • John Crown, MD, MPH

Faculty:

Mitchell Dowsett, MD, PhD headshot
  • Mitchell Dowsett, MD, PhD

CME CREDIT INFORMATION

Release Date: 01/07/08

Expiration Date: 01/06/09


Physicians: maximum of 1.0 AMA PRA Category 1 Credit(s)™

Status: Please log in to view status


Highlights from the Dublin 2007 Translational Research Meeting

Learning Objectives

Upon completion of this activity, participants should be able to:

  • Describe how estrogen receptor status aids in making treatment decisions
  • Discuss the mechanism of action of the estrogen receptor
  • Identify markers of pharmacogenomic response to hormonal therapy
  • Cite clinical trials incorporating hormonal therapy agents

Session II: Steroid Hormonal Receptors and Their Manipulation


Highlights from the Dublin 2007 Translational Research Meeting


Format: Microsoft PowerPoint (.ppt) | File size: 4,717 KB

Session III: Apoptosis and Programmed Cell Death

Program Directors:

Dennis J. Slamon, MD, PhD headshotJohn Crown, MD, MPH headshot
  • Dennis J. Slamon, MD, PhD
  • John Crown, MD, MPH

Faculty:

Gerry Melino, MD, PhD headshot
  • Gerry Melino, MD, PhD

CME CREDIT INFORMATION

Release Date: 01/18/08

Expiration Date: 01/17/09


Physicians: maximum of 1.5 AMA PRA Category 1 Credit(s)™

Status: Please log in to view status


Highlights from the Dublin 2007 Translational Research Meeting

Learning Objectives

Upon completion of this activity, participants should be able to:

  • Describe how caspase activation plays a role in apoptosis
  • Discuss how the ITCH inhibitors play a role in p63 and p73 oncogenic pathways
  • Identify how proteolytic degradation of p53 family members by caspases plays a role in cancer
  • Cite the role of B-Raf in apoptosis
  • Discuss the role of TRAIL receptor agonists as anticancer therapeutic agents

Session III: Apoptosis and Programmed Cell Death


Highlights from the Dublin 2007 Translational Research Meeting


Format: Microsoft PowerPoint (.ppt) | File size: 7,825 KB

Session IV: Malignant Angiogenesis and Antiangiogenic Therapies

Program Directors:

Dennis J. Slamon, MD, PhD headshotJohn Crown, MD, MPH headshot
  • Dennis J. Slamon, MD, PhD
  • John Crown, MD, MPH

Faculty:

Fairooz Kabbinavar, MD headshot
  • Fairooz Kabbinavar, MD

CME CREDIT INFORMATION

Release Date: 01/07/08

Expiration Date: 01/06/09


Physicians: maximum of 1.0 AMA PRA Category 1 Credit(s)™

Status: Please log in to view status


Highlights from the Dublin 2007 Translational Research Meeting

Learning Objectives

Upon completion of this activity, participants should be able to:

  • Describe the role of vascular endothelial growth factor in tumor growth
  • Discuss combinations of antiangiogenic and chemotherapeutic agents used in the treatment of cancer
  • Identify novel antiangiogenic agents used in the treatment of cancer

Session IV: Malignant Angiogenesis and Antiangiogenic Therapies


Highlights from the Dublin 2007 Translational Research Meeting


Format: Microsoft PowerPoint (.ppt) | File size: 9,524 KB

Session V: Signal Transduction: Targets in the Malignant Signaling Process

Program Directors:

Dennis J. Slamon, MD, PhD headshotJohn Crown, MD, MPH headshot
  • Dennis J. Slamon, MD, PhD
  • John Crown, MD, MPH

Faculty:

Spiros Linardopoulos, PhD headshot
  • Spiros Linardopoulos, PhD

CME CREDIT INFORMATION

Release Date: 01/07/08

Expiration Date: 01/06/09


Physicians: maximum of 1.0 AMA PRA Category 1 Credit(s)™

Status: Please log in to view status


Highlights from the Dublin 2007 Translational Research Meeting

Learning Objectives

Upon completion of this activity, participants should be able to:

  • Describe the role that Src inhibitors play in oncogenic pathways
  • Discuss how the hedgehog pathway plays a key role during embryogenesis and is reactivated in a subset of human malignancies
  • Identify the role of Chk inhibitors in the treatment of cancer
  • Cite the role that aurora kinase inhibitors play in mitosis

Session V: Signal Transduction: Targets in the Malignant Signaling Process


Highlights from the Dublin 2007 Translational Research Meeting


Format: Microsoft PowerPoint (.ppt) | File size: 3,595 KB

Session VI: Immunotherapies and Vaccine Strategies

Program Directors:

Dennis J. Slamon, MD, PhD headshotJohn Crown, MD, MPH headshot
  • Dennis J. Slamon, MD, PhD
  • John Crown, MD, MPH

Faculty:

John Glaspy, MD headshot
  • John Glaspy, MD

CME CREDIT INFORMATION

Release Date: 01/28/08

Expiration Date: 01/27/09


Physicians: maximum of 1.0 AMA PRA Category 1 Credit(s)™

Status: Please log in to view status


Highlights from the Dublin 2007 Translational Research Meeting

Learning Objectives

Upon completion of this activity, participants should be able to:

  • Describe the mechanism of action of CTLA4
  • Discuss how CTLA4-blocking monoclonal antibodies can lead to sustained regression of tumors in patients
  • Summarize vaccine combinations with anti-CTLA4 blockade
  • Cite the rationale for MAGE-A3 as an antitumor target

Session VI: Immunotherapies and Vaccine Strategies


Highlights from the Dublin 2007 Translational Research Meeting


Format: Microsoft PowerPoint (.ppt) | File size: 4,678 KB

Session VII: Malignant Stem Cells as Targets in Oncology

Program Directors:

Dennis J. Slamon, MD, PhD headshotJohn Crown, MD, MPH headshot
  • Dennis J. Slamon, MD, PhD
  • John Crown, MD, MPH

Faculty:

Hasan Korkaya, PhD headshot
  • Hasan Korkaya, PhD

CME CREDIT INFORMATION

Release Date: 01/28/08

Expiration Date: 01/27/09


Physicians: maximum of 1.0 AMA PRA Category 1 Credit(s)™

Status: Please log in to view status


Highlights from the Dublin 2007 Translational Research Meeting

Learning Objectives

Upon completion of this activity, participants should be able to:

  • Discuss the role of Wnt signaling in cancer and cancer stem cells
  • Describe the action of transforming growth factor beta in normal and malignant cells
  • Explain the therapeutic use of PARP inhibition in cancer treatment
  • Summarize the effect of HER2 overexpression on cancer stem cell growth

Session VII: Malignant Stem Cells as Targets in Oncology


Highlights from the Dublin 2007 Translational Research Meeting


Format: Microsoft PowerPoint (.ppt) | File size: 9,279 KB

Session VIII: New Approaches to Pathway Identification, Predictive/Prognostic Factors, and Biologic Imaging Markers

Program Directors:

Dennis J. Slamon, MD, PhD headshotJohn Crown, MD, MPH headshot
  • Dennis J. Slamon, MD, PhD
  • John Crown, MD, MPH

Faculty:

John Crown, MD, MPH headshot
  • John Crown, MD, MPH

CME CREDIT INFORMATION

Release Date: 01/09/08

Expiration Date: 01/08/09


Physicians: maximum of 0.75 AMA PRA Category 1 Credit(s)™

Status: Please log in to view status


Highlights from the Dublin 2007 Translational Research Meeting

Learning Objectives

Upon completion of this activity, participants should be able to:

  • Describe the use of flow cytometry for studying cell signaling mechanisms in cancer
  • Discuss molecular subtypes in ovarian cancer
  • Cite epidemiology of ovarian cancer

Session VIII: New Approaches to Pathway Identification, Predictive/Prognostic Factors, and Biologic Imaging Markers


Format: Microsoft PowerPoint (.ppt) | File size: 4,099 KB
Disclaimer: The materials published on the Clinical Care Options Web site reflect the views of the reviewers or authors of the CCO material, not those of Clinical Care Options, LLC, the CME provider, or the companies providing educational grants. The materials may discuss uses and dosages for therapeutic products that have not been approved by the United States Food and Drug Administration. A qualified healthcare professional should be consulted before using any therapeutic product discussed. Readers should verify all information and data before treating patients or using any therapies described in these materials.

Jointly sponsored by Postgraduate Institute for Medicine and Clinical Care Options, LLC.

Contact Info

Educational grants provided by:

Educational grants support only the CME-certified components of this program.